Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA)

Invest Radiol. 2007 Jan;42(1):58-62. doi: 10.1097/01.rli.0000248893.01067.e5.

Abstract

Objective: The purpose of this study was to assess the diagnostic value and safety of the contrast agent gadoterate meglumine (Gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex, France) in the setting of a postmarketing surveillance study.

Materials and methods: Between January 2004 and October 2005, radiologists in 61 radiologic institutions were asked to document the routine use of Gd-DOTA in a questionnaire. In addition to assessing the image quality and diagnostic value of the contrast-enhanced magnetic resonance imaging scans, we statistically evaluated and analyzed demographic and safety data.

Results: A total of 24,308 patients were intravenously injected with Gd-DOTA for various diagnostic examinations. The examination allowed for establishing a diagnosis in >99% of cases and image quality was rated as "excellent" or "good" in 97.5% of all cases. Adverse events were noted in only 0.4% of the examinations and were mostly rated as minor, such as feeling of warmth or taste alteration. There was one serious adverse event, albeit with complete recovery.

Conclusion: This postmarketing surveillance study suggests diagnostic efficacy and a favorable clinical safety profile of Gd-DOTA in clinical practice.

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Chi-Square Distribution
  • Contrast Media / administration & dosage
  • Contrast Media / adverse effects
  • Female
  • Humans
  • Injections, Intravenous
  • Magnetic Resonance Imaging*
  • Male
  • Meglumine* / administration & dosage
  • Meglumine* / adverse effects
  • Organometallic Compounds* / administration & dosage
  • Organometallic Compounds* / adverse effects
  • Product Surveillance, Postmarketing
  • Safety*
  • Surveys and Questionnaires

Substances

  • Contrast Media
  • Organometallic Compounds
  • Meglumine
  • gadoterate meglumine